Risque d'événements cardiovasculaires indésirables majeurs chez les patients initiant un traitement biologique /Aprémilast pour le rhumatisme psoriasique : Une étude de cohorte à l'échelle nationale
doi: 10.1093/rheumatology/keab522
Pina Vegas and her colleagues sought to assess the relative risk of MACEs in patients with PsA initiating bDMARDs or apremilast. They found that overall, the data produced overall a positive picture regarding the incidence of MACE in treatment.
In this investigation Pina Vegas and her team undertook a nationwide cohort study. This study utilised two key databases: that of the French National Health Insurance and the National hospital discharge. Their primary endpoint was the occurrence of MACE amongst the participants, an event which was defined as a combination of acute myocardial infarction and ischaemic stroke.
In addition to their main findings researchers also found that there was an increased risk of MACEs in new users of IL-12/23i and IL-17i vs TNFi in PsA. This suggests that TNFi therapy should be the first second-line therapy utilised in PsA, especially for patients with high CVD risk
Keywords:
